References
- Greenblatt M S, Bennett W P, Hollstein M, Harris C C. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855–4878
- Malkin D, Li F P, Strong L C, Fraumeni J J, Nelson C E, Kim D H, Kassel J, Gryka M A, Bischoff F Z, Tainsky M A, Friend S H. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233–1238
- Srivastava S, Zou Z Q, Pirollo K, Blattner W, Chang E H. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747–749
- Donehower L A, Harvey M, Slagle B L, McArthur M J, Montogomery CA, Jr, Butel J S, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215–221
- Kastan M B, Zhan Q, El-Dairy E S, Carrier F, Jacks T, Walsh W V, Plunkett B S, Vogelstein B, Fornace AJ, Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587–597
- El-Deiry W S, Tokino T, Veculescu V E, Levy D B, Parsons R, Trent J M, Lin D, Mercer W E, Kinzler K W, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817–825
- Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO 1994; J 13: 4816–4822
- Miyashita T, Reed J C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293–299
- Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger B R, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995; 377: 646–649
- Kato M V, Sato H, Nagayoshi M, Ikawa Y. Upregulation of the elongation factor-1 α gene by p53 in association with death of an erythroleukemic cell line. Blood 1997; 90: 1373–1378
- Kato M V, Sato H, Ishizaki K, Nagayoshi M, Ikawa Y. No significant changes in the expression of the fas, fast, bcl-2 and bax genes in apoptosis of an erythroleukemic cell line by p53. Int J Oncol 1996; 9: 269–277
- Liang P, Pardee A B. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257: 967–971
- El-Deiry W S, Kern S E, Pietenpol J A, Kinzler K W, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45–49
- Kaziro Y. The role of guanosine 5′-triphosphate in polypeptide chain elongation. Biochim Biophys Act 1978; a 505: 95127
- Shiina N, Gotoh Y, Kubomura N, Iwamatsu A, Nishida E. Microtubule severing by elongation factor 1 alpha. Science 1994; 266: 282–285
- Murphy M, Hinman A, Levine A J. Wild-type p53 negatively regulates the expression of a microtubule-associated protein. Genes Dev 1996; 10: 2971–2980
- Blagosklonny M V, Giannakakou P, El-Deiry W S, Kingston D G, Higgs P I, Neckers L, Fojo T. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 1997; 57: 130–135
- Bates S, Rowan S, Vousden K H. Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 1996; 13: 1103–1109
- Okamoto K, Kamibayashi C, Serrano M, Prives C, Mumby M C, Beach D. p53-dependent association between cyclin G and the B' subunit of protein phosphatase 2A. Mol. Cell. Biol. 1996; 16: 6593–6602
- Kanaoka Y, Kimura S H, Okazaki I, Ikeda M, Nojima H. GAK: a cyclin G-associated kinase contains a tensin/auxilin-like domain. FEBS Lett 1997; 402: 73–80
- Iwata S, Ostermeier C, Ludwig B, Michel H. Structure at 2.8 Å resolution of cytochrome c oxidase from Paracoccus denitrificans. Nature 1995; 376: 660–669
- Tsukihara T, Aoyama H, Yamashita E, Tomizaki T, Yamaguchi H, Shinzawa-Itoh K, Nakashima R, Yaono R, Yoshikawa S. The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 Å. Science 1996; 272: 1136–1144
- Wu L, Liu L, Yee A, Carbonaro-Hall D, Tolo V T, Hall F L. Molecular cloning of the human CYCG1 gene encoding a G-type cyclin: overexpression in human osteosarcoma cells. Oncology Reports 1994; 1: 705–711
- Liu X, Kim C N, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147–157
- Yang J, Liu X, Bhalla K, Kim C N, Ibrado A M, Cai J, Peng TI, Jones D P, Wang X. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129–1132
- Kluck R M, Bossy-Wetzel E, Green D R, Newmeyer D D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997; 275: 1132–1136
- Leist M, Single B, Castoldi A F, Kuhnle S, Nicotera P. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis. J Exp Med 1997; 185: 1481–1486
- Eguchi Y, Shimizu S, Tsujimoto Y. Intracellular ATP levels determine cell death fate by apoptosis or necrosis. Cancer Res 1997; 57: 1835–1840
- Zou H, Henzel W J, Liu X, Lutschg A, Wang X. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 1997; 90: 405–413
- Enari M, Sakahira H, Yokoyama H, Okawa K, Wamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998; 391: 43–50
- Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998; 391: 96–99
- Capaldi R A, Marusich M F, Taanman J W. Mammalian Cytochrome-c Oxidase: Characterization of Enzyme and Immunological Detection of Subunits in Tissue Extracts and Whole Cells. Methods Enzymol. 1995; 260: 117–132